Oregon is currently home to 1209 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Portland, Eugene, Medford and Clackamas. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Vestibulectomy Surgical Techniques Comparison Study
NCT05343182
Recruiting
Vestibulectomy Surgical Techniques Comparison Study
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
09/06/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Vulvar Pain, Vulvodynia
Register for Updates
Safety Study of PP-007 in Subjects With Acute Ischemic Stroke
NCT04677777
Recruiting
The HEMERA-1 Extension (Part III) is a prospective, open-label, multicenter study to evaluate safety of two doses of PP-007 in Acute Ischemic Stroke (AIS) subjects receiving Intravenous Thrombolysis (IVT) or mechanical thrombectomy (MT) or IVT+MT as standard of care (SOC). Subjects will receive two doses of PP-007 infusion 24 ± 6 hours apart in addition to the site-specific SOC protocol. PP-007 is PEGylated bovine carboxyhemoglobin and will be administered via IV infusion. The effects on collate... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/28/2024
Locations: Oregon Stroke Center at Oregon Health & Science University (OHSU), Portland, Oregon
Conditions: Acute Ischemic Stroke
Register for Updates
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
NCT05870748
Recruiting
A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: Oncology Associates of Oregon, PC, Eugene, Oregon
Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
Register for Updates
A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)
NCT06305234
Recruiting
This is a 10-year multi-center, prospective, longitudinal, single arm study evaluating immunologic, inflammatory and laboratory parameters associated with long-term Palynziq treatment in subjects with phenylketonuria (PKU) in the United States (US). Subjects in the US for whom a clinical decision has been made that they will receive pegvaliase to treat their PKU within 30 days following the date of enrollment in Study 165-501 (incident-users) or who have previously started treatment with pegvali... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/23/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Phenylketonuria (PKU)
Register for Updates
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
NCT05548283
Recruiting
The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or IV). A pulmonary exacerbation is a worsening of respiratory symptoms in people with CF that needs medical intervention. Both doctors and CF patients are trying to understand the best way to treat pulmonary exacerbations. This study is trying to answer the following questions about treating a pulmonar... Read More
Gender:
ALL
Ages:
6 years and above
Trial Updated:
08/23/2024
Locations: Oregon Health Sciences University, Portland, Oregon
Conditions: Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
Register for Updates
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
NCT04071457
Recruiting
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Ste... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/21/2024
Locations: Saint Alphonsus Cancer Care Center-Baker City, Baker City, Oregon
Conditions: Multiple Myeloma
Register for Updates
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
NCT02559778
Recruiting
A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
Gender:
ALL
Ages:
22 years and below
Trial Updated:
08/21/2024
Locations: Randall Children's Hospital, Portland, Oregon
Conditions: Neuroblastoma
Register for Updates
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
NCT05011383
Recruiting
This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therapy may result in responses in tumors which are genetically unstable because of DNA repair deficiency and this is a prospective study to test that hypothesis
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/19/2024
Locations: VA Portland Health Care System, Portland, OR, Portland, Oregon
Conditions: Metastatic Prostate Cancer
Register for Updates
Catalyst CSR Shoulder System for Semi or Total Shoulder Arthroplasty
NCT04968405
Recruiting
Evaluation of the performance and safety of the Catalyst CSR Shoulder System with clinical and radiographic results at multiple time points through 24 months postoperatively This study will be a prospective multi-center study conducted in the United States.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2024
Locations: Kaiser Permanente Northwest Center for Health Research, Portland, Oregon
Conditions: Osteoarthritis Shoulder, Avascular Necrosis of the Head of Humerus, Rheumatoid Arthritis Shoulder
Register for Updates
Center M: Digital Health Innovation Pilot
NCT06000449
Recruiting
Center M is a digital health solution to Perinatal Depression (PD) which provides an alternative to Mindfulness Based Cognitive Therapy - Perinatal Depression (MBCT-PD). Center M shifts treatment to a telehealth model, reduces the number of sessions, and transitions home practice materials to a digital format. This study will include a clinical trial in which participants will be randomized to the Center M treatment with smartphone app delivery of homework compared to treatment as usual (TAU).
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
08/16/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Perinatal Depression
Register for Updates
PAI-1, tPA, TFPI and HEECs in Uterine Hemostasis
NCT05862805
Recruiting
The purpose of the study is to learn more about the role of blood clotting factor proteins and cells in menstrual (period) bleeding. The investigators are hoping to identify differences in these proteins and cells in the menstrual blood of individuals with heavy periods compared to menstruating individuals who do not have heavy periods.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
08/16/2024
Locations: OHSU, Portland, Oregon
Conditions: Menstrual Bleeding, Heavy
Register for Updates
Disparities in Emergency Contraceptive Metabolism Dictate Efficacy
NCT05674513
Recruiting
The purpose of this study is to learn more about why some people are at greater risk for oral emergency contraceptive failure while others are not. The investigators want to learn if genetic differences impact the risk of emergency contraception failure.
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
08/16/2024
Locations: OHSU, Portland, Oregon
Conditions: Contraceptive Usage
Register for Updates